(3S,5S)-Atorvastatin Sodium Salt CAS: 501121-34-2
MF: C33H34FN2NaO5
MW: 580.62
A selective, competitive HMG-CoA reductase inhibito.

(3S,5S)-Atorvastatin Sodium Salt (CAS 501121-34-2)

(3S,5S)-Atorvastatin Sodium Salt | CAS 501121-34-2 is rated 5.0 out of 5 by 1.
  • y_2020, m_7, d_15, h_15
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.10
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_206739, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 143ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Alternate Names: (βS,δS)-2-(4-Fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic Acid Sodium; 3S,5S-Atorvastatin Sodium
Application: (3S,5S)-Atorvastatin Sodium Salt is a selective, competitive HMG-CoA reductase inhibito
CAS Number: 501121-34-2
Purity: 95%
Molecular Weight: 580.62
Molecular Formula: C33H34FN2NaO5
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data (including water content).

(3S,5S)-Atorvastatin Sodium Salt is a selective, competitive HMGCR (HMG-CoA reductase) inhibitor.


References

Kearney, A.S., et al.: Pharm. Res., 10, 1461 (1993), Heinonen, T.M., et al.: Clin. Ther., 18. 853 (1996), Whitfield, L.R., et al.: Eur. J. Drug Metab. Pharmacokinet., 25, 97 (2000)

Physical State :
Solid
Solubility :
Soluble in chloroform, DMSO, and methanol.
Storage :
Store at -20° C
Melting Point :
190-193° C
Refractive Index :
n20D ~1.60 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
46780491
MDL Number :
MFCD18251281
SMILES :
CC(C)C1=C(C(=C(N1CC[[email protected]@H](C[[email protected]@H](CC(=O)[O-])O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4.[Na+]

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 136ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Potey Potey, C. et al. (PubMed 26289767) reported that early treatment with the HMG-CoA reductase inhibitor (3S,5S)-Atorvastatin exerts parenchymal and vascular protective effects in experimental cerebral ischemia. -SCBT Publication Review
Date published: 2015-04-24
  • y_2020, m_7, d_15, h_15
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.10
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_206739, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 16ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.